clinical trials

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

R&D

This week in clinical trials: 20th to 24th May

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards.

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

R&D

Challenges and opportunities in synthetic clinical trials

Of the many changes coming to clinical trials, one of the biggest potential paradigm shifts on the horizon is the elimination of placebo groups in some trials in favour of synthetic control

News

GSK’s twice-yearly asthma drug clears two phase 3 trials

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

This week in clinical trials: 20th to 24th May

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

Challenges and opportunities in synthetic clinical trials

GSK’s twice-yearly asthma drug clears two phase 3 trials

23andMe study explains variable results with obesity drugs

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks